K. Chapman (Toronto (ON), Canada), M. Vukoja (Sremska Kamenica, Republic of Serbia)
Late Breaking Abstract - Azithromycin for acute COPD exacerbations requiring hospitalization – the BACE trial results
K. Vermeersch (Leuven, Belgium), M. Gabrovska (Brussel, Belgium), J. Aumann (Hasselt, Belgium), I. Demedts (Roeselare, Belgium), J. Corhay (Luik, Belgium), E. Marchand (Yvoir, Belgium), H. Slabbynck (Antwerpen, Belgium), C. Haenebalcke (Brugge, Belgium), M. Haerens (Kortrijk, Belgium), S. Hanon (Brussel, Belgium), P. Nguyen (Aalst, Belgium), R. Peché (Charleroi, Belgium), A. Fremault (Charleroi, Belgium), T. Lauwerier (Bonheiden, Belgium), B. Vandenberk (Leuven, Belgium), S. Everaerts (Leuven, Belgium), V. Ninane (Brussel, Belgium), G. Verleden (Leuven, Belgium), T. Troosters (Leuven, Belgium), K. Bogaerts (Leuven, Belgium), G. Brusselle (Gent, Belgium), W. Janssens (Leuven, Belgium)
|    |
COPD exacerbations in the phase 3 revefenacin clinical trial program
J. Donohue (Chapel Hill, NC, United States of America), S. Sethi (Buffalo, NY, United States of America), C. Barnes (South San Franscico, CA, United States of America), E. Moran (South San Franscico, CA, United States of America), S. Pendyala (South San Franscico, CA, United States of America), G. Crater (South San Franscico, CA, United States of America), B. Haumann (London, UK, United Kingdom)
|  |
Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients
I. Psallidas (Gothenburg, Sweden), C. Astbury (Barcelona, Spain), L. Jimenez (Barcelona, Spain), U. Walby Hamren (Gothenburg, Sweden), B. Seoane (Barcelona, Spain), M. Malice (Barcelona, Spain), V. Balaguer (Barcelona, Spain), A. Lei (Barcelona, Spain), A. Aggarwal (Boston, United States of America), D. Singh (Manchester, United Kingdom)
| |
Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study
K. Kostikas (Basel, Switzerland), A. Mackay (London, United Kingdom), C. Vogelmeier (Marburg, Germany), S. Frent (Timisoara, Romania), P. Pfister (Basel, Switzerland), P. Gupta (Hyderabad, India), D. Banerji (East Hanover, United States of America), F. Patalano (Basel, Switzerland), J. Wedzicha (London, United Kingdom)
| |
Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial
M. Tabberer (Middlesex, United Kingdom), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Middlesex, United Kingdom), G. Criner (Philadelphia, United States of America), P. Lange (Copenhagen, Denmark), M. Han (Ann Arbor, United States of America), F. Martinez (New York, United States of America), D. Lipson (King of Prussia, United States of America)
| |
Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), N. Roche (Paris, France), M. Corradi (Parma, Italy), A. Guasconi (Parma, Italy), M. Scuri (Parma, Italy), I. Montagna (Parma, Italy), G. Cohuet (Parma, Italy), C. Francisco (Parma, Italy), S. Vezzoli (Parma, Italy), S. Petruzzelli (Parma, Italy), A. Papi (Ferrara, Italy)
| |
Economic and quality of life consequences of clinically important deterioration in patients with COPD: results from the TORCH study
A. Ismaila (Collegeville, PA, United States of America), M. Driessen (Brentford, United Kingdom), A. Briggs (Glasgow, Scotland, United Kingdom), N. Risebrough (Toronto, ON, Canada), I. Naya (Brentford, United Kingdom), N. Gunsoy (Stockley Park, Uxbridge, United Kingdom), V. Paly (Philadelphia, PA, United States of America)
| |
KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD
G. Ferguson (Farmington Hills, United States of America), K. Rabe (Kiel, Germany), F. Martinez (New York, United States of America), L. Fabbri (Gothenberg, Sweden), C. Wang (Beijing, China), M. Ichinose (Sendai, Japan), E. Bourne (Durham, United States of America), S. Ballal (Morristown, United States of America), K. Deangelis (Durham, United States of America), M. Aurivillius (Mölndal, Sweden), P. Dorinsky (Durham, United States of America)
| |